April 2025 Newsletter

This month, we delve into one of the most groundbreaking developments in melanoma research: vaccines. Our spotlight article examines the potential of mRNA vaccines and explores the progress researchers have made toward creating a melanoma-specific vaccine.You’ll also find the latest installment of our Side Effect Central series—this issue covers lichen planus, an inflammatory skin condition that can appear during treatment with immunotherapy, with insights to help patients and caregivers understand and manage this potential side effect.
We also highlight a compelling study on indoor tanning behaviors, revealing how some individuals continue to tan indoors despite knowing the serious health risks—offering new understanding around the concept of behavioral addiction.
Whether you want to stay updated on the latest melanoma research, support a loved one facing the disease, or expand your understanding of it, this issue is filled with valuable insights and resources to guide you.
Read. Learn. Stay connected with AIM.
Recent Posts

Melanoma Monday: Every Day. Everywhere.

Lilly Pulitzer and AIM at Melanoma Partner for 5th Annual Community Giving Event

KIMMTRAK doubles the likelihood of being alive at five years for firstline HLA-A*02:01+ patients with metastatic uveal melanoma

FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients


